The 60,000 companies that supply materials, products and services to Novo Nordisk will by 2030 have to ensure that the delivery to Novo Nordisk is performed in a manner that is CO2 neutral, or they will lose Novo Nordisk as customer.
Thus dictates a decree that Novo Nordisk has issued to its suppliers as part of the company's environmental strategy Circular for Zero, which aims to ensure that the company has zero impact on the environment.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.